During 1995 the World Health Organization reviewed data on Methods human immunodeficiency virus (HIV) infections, acquired
Estimation methodologies immunodeficiency syndrome (AIDS) cases, and HIV-associated ... , , . . ,, , , consistent with results from each method. These estimates give an indication of the magnitude of levels of HIV infection and provide a baseline for the future monitoring Enumeration of the HIV pandemic at the national, regional, and global level.
Because detection of HIV infection is limited by the long and Furthermore, we anticipate that these estimates will help varied subclinical nature of the infeaion and differential access ensure that adequate programmes are put in place for both t 0 health care and HIV testin 8 facilities, enumerated or detected HIV/AIDS prevention and care and may facilitate rational HIV infections underrepresent the actual number of individuals decision making regarding resource allocation. Estimation of '"fected with HIV. Reported HIV infections have been used only HIV prevalence involves a variety of methods and processes that t 0 establish an absolute minimum number of HIV infections in are described in this paper. t h e absence of other data.
Population-based probability sampling
The most reliable estimate of HIV prevalence could be obtained Surveillance, Evaluation',' and Forecasting Unit, Global Programme on AIDS, b V serosurveys based on probability sampling of the population. World Health Organization, 1211 Geneva, Switzerland
In many countries the prevalence is low and a large sample size would be required. Until recently, blood had to be drawn for HIV testing and, therefore, consent had to be obtained leading to the possibility of severe participation bias. 2 If HIV infection is limited to 'high risk' populations, access to these populations may be difficult. To date, due to ethical, logistical, financial and methodological reasons, few population-based surveys have been conducted. Modelling Modelling provides a useful tool to test the consistency of estimates derived from multiple types of data. For example, an estimate of HIV prevalence should be consistent with information on reported AIDS cases, assumptions of AIDS case reporting biases, findings from HTV seroprevalence studies, observations on the progression from infection to AIDS, and knowledge of the epidemiological patterns of HIV in the population. We have used EpiModel 3 to explicitly explore the consistency of our estimate with the different data available for each country.
Expert judgement
In situations where data on HIV/AIDS levels, trends, and distributions are limited, expert judgement can provide insight as to the likely range of HIV prevalence. Valuable types of expertise include knowledge of local transmission patterns, HTV epidemiology, and formal epidemic theory. We have drawn extensively on all three types of expertise. Extrapolation The recent past is often the best predictor of the present. In situations where 1994 data were not available we have used simple mathematical techniques to extrapolate from recent data to establish the most likely present estimate.
Aggregation of seroprevalence surveys
Results of HIV prevalence surveys may be applied to the population the study group represents. If the epidemic appears to be confined to 'high risk' populations, an estimate of total prevalence may be derived from applying the results of prevalence surveys to the estimated total size of these populations. If prevalence levels vary between groups it is necessary to make a separate estimate for each group and sum these populationspecific estimates. For example, in many countries HIV levels vary between urban and rural areas. In this instance an estimate should be made for each area and aggregated for a national estimate. In general, the following formula is applied:
where pi is the number positive in the group tested, ti is the number tested in the group and Ri is the estimated size of the population size for which (pi/ti) may be applied.
Care should be taken that the groups do not overlap and all groups are included.
Exogenous data
In some cases HTV/AIDS data have not been available or the data available have been of poor quality or older than 5 years. In these instances we have made estimations based on information from similar countries with a better documented epidemic.
In some cases National AIDS Programmes have made estimates based upon extensive seroprevalence studies (primarily HIV sero-surveillance), using relatively complete AIDS case and mortality reporting, and fairly sophisticated mathematical modelling. For countries that have undertaken such an exercise we have used their estimates (e.g. 4 ' 5 ).
Other countries have made national estimates of cumulative HIV incidence and in these circumstances we have attempted to derive a prevalence estimate that is consistent with the cumulative incidence estimate and information regarding HIVassociated mortality, the age of the epidemic, and the most likely shape of the HIV incidence curve (e.g. 6 ).
When national estimates were not available or were not based on extensive data sources, we have used all of the methods above for which there was data. Firstly, subpopulations in which there is evidence of HIV infection were identified by reviewing all HIV/AIDS data available. Secondly, prevalence studies were reviewed taking into account their methodological qualities described below. Thirdly, using all remaining seroprevalence data points to provide upper and lower limits, a conservative estimate (i.e. usually lower than the median value of all prevalence levels) was made for each subpopulation, taking into account seroprevalence trends over the past 2 years. Fourthly, the best available information was used to estimate the size of the subpopulations. Finally, the estimated prevalence rates were applied to the estimated sizes of subpopulations and the weighted results were totalled to provide an estimate of the prevalence of HTV infection for the country.
For countries where the epidemic has been poorly documented, we have applied the estimation procedure outlined above as far as possible, supplementing sparse country-specific information with insights from similar, better studied epidemics. When possible we have nearly always examined the assumptions and estimates together with local and regional experts to arrive at a provisional working estimate of end-1994 prevalence.
Once a provisional country-specific estimate was obtained, reported and estimated AIDS cases were compared with the number of AIDS cases that could be expected from estimated past and present levels of HIV infection, using modelling approaches, and the estimate was adjusted if necessary. The provisional country estimates were compared with those from other countries to determine whether they were consistent with the current regional epidemic. After preliminary estimates were made, we submitted them to local and regional experts in both WHO regional Offices, and national AIDS programmes, and independent experts, to incorporate their knowledge of local HIV/AIDS situations.
Data Sources
In making HIV prevalence estimates we have relied on various types of data from multiple sources.
AIDS cases reported to WHO
It is usual practice for AIDS cases to be officially reported to WHO in Geneva, Switzerland, from member states through WHO'S regional offices. In countries with sophisticated surveillance systems, AIDS case surveillance has provided an empirical basis for estimation of earlier patterns of HIV infections using back calculation methods and projections of future AIDS cases. For many other countries, however, the usefulness of reported AIDS cases for determining the magnitude of the epidemic is compromised by the limited access to health care for those with AIDS and the lack of resources of the health care system to diagnose patients with conditions which satisfy one of the commonly used AIDS surveillance definitions. In some developing countries, data on AIDS cases by age and sex are nevertheless useful to provide new insights into the dynamics of the epidemic and particularly on the shape of the incidence curve.
Routine HIV surveillance activities
Many countries have implemented routine HIV surveillance activities. These activities may consist of sero-surveys in which individuals are randomly selected or voluntarily recruited, reporting of identified HIV-positive individuals, and HIV sentinel sero-surveillance systems to monitor HIV trends in selected populations. Due to the use of a fairly consistent and known methodology, data from HIV sentinel sero-surveillance systems provide the richest source of information for estimating HIV prevalence. Because the biases in reporting of identified HIVinfected individuals reflect testing policies rather than the underlying level of HIV infection, reported HIV infections have been used only to establish an absolute minimum number of HIV infections.
Published studies
The scientific literature and international conferences are major sources of information relevant to HTV estimation. The usefulness of such data for estimation purposes, however, is limited by the time taken for the results of studies to appear in the literature, and the occasional omission of methodological details. And, because studies are usually undertaken for other purposes, the presentation of the results may not be organized so as to be of direct value for estimation purposes. In addition, data from routine surveillance activities, blood screening programmes, and service statistics rarely appear in the published literature. The US Bureau of the Census maintains a database of HIV prevalence data which appear in the scientific literature, the press, and international conferences, 10 which we have used extensively.
Blood banking systems
In many countries, blood donated for transfusion is screened for HIV as well as other pathogens. While HIV prevalence levels derived from such screening may not reflect the levels found in the general population due to donor selection, they have provided important information on trends in HIV infection especially during the 1980s. The large sample size usually provided by blood bank screening programmes confers an additional advantage, in that the confidence interval on the estimated seroprevalence level is relatively narrow. Where such data have been available, either through reports from Ministries of Health or as they appear in the scientific literature, they have served as important information on which to base estimates for the general population.
International requirements
In some areas, HTV testing has been practised for purposes other than public health, for example, testing of visa applicants, military recruits, and job applicants. Since the results of such testing are not representative, they have been used only when other data are not available and careful consideration has been given to potential biases.
Methodological threats to validity
When reviewing findings from studies of HIV prevalence for estimation purposes, several considerations are borne in mind and a variety of additional characteristics are used to describe the prevalence levels.
The population tested
Because HIV transmission is influenced by behaviour, different groups will exhibit different levels of HIV infection. For example, when introduced into a population of intravenous drug users who share needles, the transmission rate will be explosive due to the efficiency of transmission. Individuals with multiple sexual partners are more likely to have higher levels of transmission than some other populations. Because they are generally representative of the 'general' population, HIV prevalence studies among pregnant women provide a good, if slightly biased, indication of HIV prevalence in the sexually active adult population.
The time interval during which blood samples were drawn
The interval over which the blood samples were drawn is used to ascertain whether the HIV prevalence rate is a point estimate (i.e. over a few months) or a period estimate (i.e. over a period of more than 6 months). In a changing pattern of incidence (either rising or falling) period prevalence will be insensitive to recent changes in prevalence. 2 In an emerging epidemic, for example, period prevalence will tend to underestimate current prevalence.
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Geographical location
Levels of HIV infections are known to vary geographically and may not be uniformly distributed throughout the country. In countries with a documented large urban/rural population differences in HIV prevalence, for example, estimates of urban/ rural-specific prevalence rates are calculated and weighted to reach the final estimate.
Enrolment method
Seroprevalence estimates may be baiased depending on the enrolment method used. Unlinked anonymous testing of blood drawn for other purposes minimizes bias due to differential participation, while the results of voluntary and mandatory testing will usually be affected by participation bias.
Sample size
Finally, sample size influences the precession of the HIV prevalence estimates from studies. WHO/Global Programme on AIDS (GPA) has used a minimum of 200 as the lowest acceptable sample size except in circumstances where virtually no data were available.
The Example of India
During 1994 and 1995, we collaborated with the National AIDS Control Organization, Government of India, to estimate the number of adults living with HIV infection." We describe a number of scenarios using a variety of data and assumptions which gave a range of estimates from 840 000 to 3 000 000 adult HIV infections in India as of the end of 1994.
The first scenario involved making a crude national estimate. Between 1985 and February 1995, 2 460 075 blood samples were screened for the presence of HIV antibodies. Of these, 17 830 tested positive and were confirmed with Western Blot. The overall period prevalence rate was 7.25 per 1000 for the 10-year period. Applying this rate to the Government of India's 1991 Census of 448 992 083 adults aged 15-49 years gives one an estimate of over 3 million adults.
The second scenario involved making state-specific estimates. To account for geographical variation we then disaggregated the above data by 35 States. Period seroprevalence rates ranged from 4 per 10 000 to just below 10%. By applying the statespecific prevalence rate to the state-specific adult population aged 15-49 years one estimates approximately 2 500 000 adult HIV infections.
The third scenario involved making state specific estimates based on the urban population. Experience from other countries suggests that the majority of infections are confined to the urban areas in the early stages of the epidemic. If HIV testing has been confined to urban settings and the majority of HIV infections have occurred in urban setting a conservative estimate could be reached by applying the state specific urban population to the state-specific period prevalence. This gives an estimate of 915 000 adult HTV infections.
The fourth scenario was a state specific number based on urban and rural infections. The assumption of no infections in the rural area may be overly conservative. In the absence of rural data we assumed that rural period prevalence rate was 10% of the state-specific seroprevalence prevalence rate. We then calculated for each state the number of rural infections and the number of urban infections. Summing these gave a national figure of 1 000 000 adult HIV infections.
The above scenarios assume that seroprevalence rates are unbiased and the different estimates of the number of HIV infected adults result from applying these seroprevalence rates to different populations. These seroprevalence rates, however, are likely to be biased in two important ways. Firstly, the data represent a 10-year period prevalence rate most likely leading to an underestimate for the more recent prevalence levels. Secondly, the individuals tested have not been selected to allow generalization to a broader population. Therefore, we proposed a fifth scenario that was endorsed by both WHO and the Indian National AJDS Control Organization.
The fifth scenario was based on data from 1994 sentinel serosurveillance. To address both biases we reviewed the data from the March 1995 round of sentinel sero-surveillance. The HIV seroprevalance rates among sexually transmitted disease clinic (STD) attendees ranged from 0.0% in Port Blair to 25.5% in Bombay with a median of 6.75%. These recent 'high' estimates set an upper limit on the estimate applicable to the general population. Data from antenatal clinic (ANC) attendees collected during the same period ranged from 0.0% to 2.5% in Bombay. Assuming a 1 % urban prevalence rate (includes ANC and STD) and a 0.1% rural prevalence rate gives a national estimate of 1 260 000 urban infections, 323 000 rural infections for a total of 1 583 000 adult HIV infections. In addition, adding the estimated 150 000 HIV infected commercial sex workers (CSW) (15% HIV prevalence among approximately 1 million CSW) with 25 000 infections among injecting drug users produces an estimate of 1 758 000. This estimate falls within the ranges provided by the scenarios above, is based on recent data, and is consistent with previous estimates.
The precision of these estimates could be improved by better reporting of data from regular screening programmes, more extensive sentinel surveillance data in STD and ANC clinics, and by studies to assess the situation in the rural areas.
When possible regular screening programmes should report the 'risk behaviours' of all those screened, not only of the HTV positive individuals but also of the HIV negative individuals. This would allow stratified estimates and minimize the sampling bias. Cumulative data from regular screening programmes should not be reported. If annual numbers cannot be supplied then the data could be presented as cumulative and the most recent complete year.
It appears that HIV infections are not uniformly distributed through the country. A good geographical distribution of the sentinel surveillance network where population data are also known will improve the estimation. Finally, if in some areas, rural data can supplement data from urban settings, this will provide information for estimating rural levels of HIV throughout the country.
Gaining an accurate picture of HIV spread across different parts of India is difficult because of the variability of the epidemiological environments, the multitude of urban and semiurban areas and the lack of consistency in serological surveys regarding the period and population tested. The estimate of 1 750 000 is, therefore a preliminary working estimate. The range of precision around the estimate is quite large. It is unlikely that there were fewer than 750 000 infections or more than 3 000 000 as of the end of 1994.
Results and Comments
Globally, an estimated 16.9 million adults were living with HIV infection at the end of 1994 in countries with an adult population greater than 100 000 (Table 1) . Table 2 shows that about 66% of these infections were in sub-Saharan Africa (11 161 000), and 18% in South and South-east Asia (3 081 000), with Australasia having the fewest infections (12 000). The HIV prevalence rates ranged from less than 1 per 100 000 sexually active adult population to 18 per 100 (18%) ( Table 1) , with a median prevalence rate of 14 per 10 000. In 50 countries the prevalence rate of HIV infection was less than 5 per 10 000 sexually active adults and in 15 countries (all in sub-Saharan Africa) the prevalence rate was above 5%. The lowest prevalence rates were estimated to be in Central and East Asia and the highest in Central and Southern Africa.
Fony-three per cent of all adult HIV infections were in the least developed countries, with a further 50% of all HIV infections in developing and middle income countries, leaving 7% of all HIV infections in developed countries, using WHO'S classification. Figure la shows the HTV prevalence rate per 100 adult population by sub-continental region while Figure lb shows the proportion of adult population infected by sub-continents.
In conclusion, the estimates presented in Table 1 are provisional working estimates based on the data available to WHO as of the end of 1995. They are provisional to the degree that, despite a systematic effort to consolidate all available information, relevant data may exist of which we were not aware. In addition, in many countries surveillance activities necessary to provide a firm empirical base for estimation have not been undertaken. In other areas, civil strife and large-scale population movements compromised the accuracy of our estimates. For countries such as Rwanda, Somalia, Afghanistan, and the former Yugoslavia we have made estimates based on our suppositions of the most probable situation.
Despite the uncertainty, the figures presented are sufficiently accurate to provide an idea of the current situation. These Table 1 Provisional working estimates of number of adult HIV Table 1 empirical base necessary to increase the 3f the levels, trends, and distributions of 
